These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 27601239)

  • 1. Promoting Antibacterial Drug Development: Select Policies and Challenges.
    Sertkaya A; Jessup A; Wong HH
    Appl Health Econ Health Policy; 2017 Feb; 15(1):113-118. PubMed ID: 27601239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pull Incentives for Antibacterial Drug Development: An Analysis by the Transatlantic Task Force on Antimicrobial Resistance.
    Årdal C; Røttingen JA; Opalska A; Van Hengel AJ; Larsen J
    Clin Infect Dis; 2017 Oct; 65(8):1378-1382. PubMed ID: 29017240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibiotic research and development: business as usual?
    Harbarth S; Theuretzbacher U; Hackett J;
    J Antimicrob Chemother; 2015; 70(6):1604-7. PubMed ID: 25673635
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug and vaccine development for infectious diseases: the value of priority review vouchers.
    Matheny J; Smith B; Courtney B; Mair M
    Clin Pharmacol Ther; 2009 Jun; 85(6):571-2. PubMed ID: 19451907
    [No Abstract]   [Full Text] [Related]  

  • 5. The antibiotic pipeline: reviving research and development and speeding drugs to market.
    Luepke KH; Mohr JF
    Expert Rev Anti Infect Ther; 2017 May; 15(5):425-433. PubMed ID: 28306360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effective antibacterials: at what cost? The economics of antibacterial resistance and its control.
    White AR;
    J Antimicrob Chemother; 2011 Sep; 66(9):1948-53. PubMed ID: 21700625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic Incentives for Antibacterial Drug Development: Literature Review and Considerations From the Transatlantic Task Force on Antimicrobial Resistance.
    Sciarretta K; Røttingen JA; Opalska A; Van Hengel AJ; Larsen J
    Clin Infect Dis; 2016 Dec; 63(11):1470-1474. PubMed ID: 27578820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel approaches are needed to develop tomorrow's antibacterial therapies.
    Spellberg B; Bartlett J; Wunderink R; Gilbert DN
    Am J Respir Crit Care Med; 2015 Jan; 191(2):135-40. PubMed ID: 25590154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Societal costs versus savings from wild-card patent extension legislation to spur critically needed antibiotic development.
    Spellberg B; Miller LG; Kuo MN; Bradley J; Scheld WM; Edwards JE
    Infection; 2007 Jun; 35(3):167-74. PubMed ID: 17565458
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fighting antibiotic resistance: marrying new financial incentives to meeting public health goals.
    Kesselheim AS; Outterson K
    Health Aff (Millwood); 2010 Sep; 29(9):1689-96. PubMed ID: 20820028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of the pharmaceutical industry in meeting the public health threat of antibacterial resistance.
    Bergström R
    Drug Resist Updat; 2011 Apr; 14(2):77-8. PubMed ID: 21493123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibacterial R&D incentives.
    Laxminarayan R; Powers JH
    Nat Rev Drug Discov; 2011 Sep; 10(10):727-8. PubMed ID: 21959280
    [No Abstract]   [Full Text] [Related]  

  • 13. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America.
    Boucher HW; Talbot GH; Bradley JS; Edwards JE; Gilbert D; Rice LB; Scheld M; Spellberg B; Bartlett J
    Clin Infect Dis; 2009 Jan; 48(1):1-12. PubMed ID: 19035777
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Economic Conundrum for Antibacterial Drugs.
    Shlaes DM
    Antimicrob Agents Chemother; 2019 Dec; 64(1):. PubMed ID: 31658969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Countries mull over incentives for developing antibiotics.
    Anderson T
    Lancet; 2016 May; 387(10031):1894-5. PubMed ID: 27203638
    [No Abstract]   [Full Text] [Related]  

  • 16. Past, Present, and Future of Antibacterial Economics: Increasing Bacterial Resistance, Limited Antibiotic Pipeline, and Societal Implications.
    Luepke KH; Suda KJ; Boucher H; Russo RL; Bonney MW; Hunt TD; Mohr JF
    Pharmacotherapy; 2017 Jan; 37(1):71-84. PubMed ID: 27859453
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Public funding of clinical-stage antibiotic development in the United States and European Union.
    Eichberg MJ
    Health Secur; 2015; 13(3):156-65. PubMed ID: 26042859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Time for a change: addressing R&D and commercialization challenges for antibacterials.
    Payne DJ; Miller LF; Findlay D; Anderson J; Marks L
    Philos Trans R Soc Lond B Biol Sci; 2015 Jun; 370(1670):20140086. PubMed ID: 25918443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systems, not pills: The options market for antibiotics seeks to rejuvenate the antibiotic pipeline.
    Brogan DM; Mossialos E
    Soc Sci Med; 2016 Feb; 151():167-72. PubMed ID: 26808335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery and development of new antibacterial drugs: learning from experience?
    Jackson N; Czaplewski L; Piddock LJV
    J Antimicrob Chemother; 2018 Jun; 73(6):1452-1459. PubMed ID: 29438542
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.